Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

AI Briefing

• – Dupixent approved in Japan for adults with bullous pemphigoid, first targeted medicine for this condition, to be co-marketed by Sanofi and Regeneron.
• – The approval follows positive results from a phase III clinical trial demonstrating efficacy and safety of Dupixent in treating adults with bullous pemphigoid.
• – Dupixent is the first targeted medicine to be approved in Japan for this rare and chronic autoimmune disease, which causes blistering of the skin and mucous membranes.